EM1810H "Immune Checkpoint Inhibitor Related Endocrinopathies" (IM GR-102618)
Purpose and Overview:
Immune checkpoint inhibitors have revolutionized cancer care and are now successfully used to treat several types of cancers. Their side effect profile is distinct from the traditional chemotherapy regimens, and include immune-related adverse events. With their increased use, the frequency of these events is growing and has necessitated the development of a new form of multidisciplinary care. Immune-related endocrinopathies can significantly affect patients’ outcome and require rapid recognition and treatment. The purpose of this talk is to identify and manage the most commonly encountered endocrinopathies associated with immune checkpoint inhibitors.
Target Audience
UT Southwestern faculty, fellows, residents and medical students, community physicians, nurse clinicians, physician assistants and nurses.
Learning Objectives
At the conclusion of this activity, the participant should be able to:
- Understand the mechanism of action of immune checkpoint inhibitors
- Identify common endocrinopathies caused by immune checkpoint inhibitors
- Understand how to manage common Endocrinopathies including: hypophysitis, thyroid dysfunction and diabetes mellitus.
Sadia Ali, M.D.
Clinical Assistant Professor of Internal Medicine
Division of Endocrinology
Sadia Ali, M.D., is an Assistant Professor and Clinical Chief of the Division of Endocrinology, Diabetes and Metabolism at UT Southwestern Medical Center. Her quality improvement work has improved the management of post-transplant glycemic management at Clements University Hospital and diabetes care quality metrics at the UTSW Internal Medicine Subspecialty Clinic for Endocrinology. She is interested in high value, patient-centric, clinical care and enhancing the clinic infrastructure for the outpatient Endocrinology practice.
Available Credit
- 1.00 AMA
Price
Required Hardware/software
Activities should be run with recent versions of common browsers, including Internet Explorer, Firefox and Google Chrome